Novel PET Imaging in Prostate Cancer


Evan Y. Yu, MD, discusses the role of PET imaging in prostate cancer.

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, discusses the role of PET imaging in prostate cancer.

Clinical Pearls:

  • Various types of PET imaging can be used to help detect prostate cancer and measure prostate cancer treatment responses
  • A study that explored sodium fluoride PET as a marker in treatment response with dasatinib showed a longer progression-free survival
  • PET imaging showed that ARN-509 was hitting its intended target and helped researchers determine the optimal biologic dosing for the agent
  • Using PET imaging in clinical trials will help researchers get a better understanding the mechanism of action of some novel agents
Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content